Get the Stockscreener App
7.66
2.54%
-0.20
Blackrock Innovation And Growth Term Trust stock is traded at $7.66, with a volume of 761.28K.
It is down -2.54% in the last 24 hours and up +3,635% over the past month.
See More
Previous Close:
$7.86
Open:
$7.81
24h Volume:
761.28K
Relative Volume:
31.11
Market Cap:
$10.67M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-8.0336
EPS:
-0.9535
Net Cash Flow:
-
1W Performance:
+3,635%
1M Performance:
+3,635%
6M Performance:
+3,635%
1Y Performance:
+3,635%
1-Day Range:
$7.61
$7.81
1-Week Range:
$7.61
$8.1199
52-Week Range:
$7.61
$8.1199
Blackrock Innovation And Growth Term Trust Stock (BTX) Company Profile
Name
Blackrock Innovation And Growth Term Trust
Sector
Industry
Phone
-
Address
-
Compare BTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTX
Brooklyn Immunotherapeutics Inc
|
7.66 | 10.67M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Blackrock Innovation And Growth Term Trust Stock (BTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-06-21 | Initiated | Maxim Group | Buy |
Blackrock Innovation And Growth Term Trust Stock (BTX) Latest News
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eterna Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com India
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
BNY Mellon Ultra Short Income ETF (NYSEARCA:BKUI) Stock Price Up 0% – Should You Buy? - Defense World
Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com - Defense World
StockNews.com Begins Coverage on Avangrid (NYSE:AGR) - Defense World
General Electric (NYSE:GE) Shares Bought by Creative Planning - Defense World
Week Ahead (Apr.12- Apr.16): PDUFA Dates, Data Readouts (RCUS, ATXI, MRTX, KDNY…) - RTTNews
‘Today you’re going to die’. Man ‘disrespected’ at family event kills cousin, MN cops say - Kansas City Star
15-Year-Old Shot Outside Brooklyn High School: Police - Patch
Teen Shot Outside Brooklyn High School - BK Reader
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $87.23 Million Holdings in Intuit Inc. (NASDAQ:INTU) - MarketBeat
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Itau Unibanco Holding S.A. Takes Position in Bristol-Myers Squibb (NYSE:BMY) - Defense World
Video NYPD releases body camera video of police shooting at Brooklyn Subway station - ABC News
Brooklyn Farebeater Who Cops Shot Pleads Not Guilty From Hospital Bed - Brooklyn, NY Patch
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat
Eterna Therapeutics sets September 27 for annual meeting - Investing.com
Exclusive: RNA firm Eterna Therapeutics buys neighboring startup for $50M - The Business Journals
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights - GlobeNewswire
Kevin D’Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Business Wire
ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView
Eterna Therapeutics Completes Name Change, Acquires Option - GlobeNewswire
Brooklyn hails immunotherapy for achieving 'primary objective'—but fails the primary endpoint - Fierce Biotech
“Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy” published in Chemical Reviews, selected as VINSE Spotlight Publication - Vanderbilt University
SpyBiotech Appoints Mark Leuchtenberger as Chief Executive Officer - citybiz
iPSC-derived dopamine progenitor cell therapy in Parkinson’s disease - RegMedNet
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement - StockTitan
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index - StockTitan
Longeveron: A Meme Stock That Will Oscillate Before Dropping (NASDAQ:LGVN) - Seeking Alpha
New R&D Center Will Focus on Cell-based Therapies - Sickle Cell Disease News
7 Top-Rated Pharmaceutical Companies to Invest In for July - InvestorPlace
Swedish MPA Approves Atossa Therapeutics Inc (NASDAQ: ATOS) To Conduct Phase 2 Clinical Trial Of Oral Endoxifen To Reduce Mammographic Breast Density - BP Journal
10 Top Penny Stocks On Robinhood To Watch Right Now Before July 2021 - Penny Stocks
Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) Incorporates R&D Center In Cambridge, Massachusetts To Develop mRNA-based Gene Editing/ Cellular Therapies - BP Journal
Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal - Benzinga
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call - StockTitan
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Business Wire
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. - Business Wire
CDE China Grants IND Approval For Vicineum Of Sesen Bio Inc (NASDAQ:SESN) - BP Journal
Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics - citybiz
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Reports Strong Presence Of Clinical Trial Staff, Investigators, And Referring Physicians In A Webinar On Mino-Lok Phase 3 Clinical Trial - BP Journal
Brooklyn ImmunoTherapeutics: Time To Sell (NYSE:BTX) - Seeking Alpha
Blackrock Innovation And Growth Term Trust Stock (BTX) Financials Data
There is no financial data for Blackrock Innovation And Growth Term Trust (BTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.81%
0.82%
Cap:
|
Volume (24h):